65,437 trials
Interstitial Cystitis · Chronic Interstitial Cystitis · Bladder Pain Syndrome
Primary: Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) — 6.70 score on a scale
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Alopecia Areata
Primary: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 — 9.3; 21.4; 47.4; 58.3…
Ventral Hernia
Primary: Postoperative Pain Scores — 5; 5; 4; 3 score on a scale
Apnea, Sleep
Primary: Mean Apnea Hypopnea Index (AHI) at 6 Months Post-baseline — 9.86 No. of apneas/hypopneas per h of sleep
Tooth Extraction
Primary: Opioid Prescribing at the Extraction Encounter — 443; 643; 418 Participants — p=.08
Atopic Dermatitis
Primary: Percent Change in EASI From Baseline at Day 29 — -47.37; -42.10 percent change
Caries
Primary: Enamel Fluoride Uptake (EFU) — 2.28; 4.51; 8.78; 14.05 μg F/cm^2
Postpartum Sepsis · Postpartum Endometritis · Postpartum Fever
Primary: Number of Participants Who Experienced Composite Peripartum Infection or Death — 15; 17; 24 Participants
Arrhythmias, Cardiac
Primary: Number and Type of Clinical Actions Initiated by Reveal LINQ Arrhythmia Detection Feature — 201; 75; 32; 9 Number of times action taken
Elective Cesarean Section · Pain Management
Primary: Total Postsurgical Opioid Consumption Through 72 Hours — 69.3; 36.1; 22.1 OMED mg
Lower Extremity Surgery · Bunion · Metatarsophalangeal Fushion
Primary: Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC) — 298.65; 358.10; 380.05 score on a scale*hours
Smoking Cessation
Primary: Number of Participants Who Passed the Biochemical Validated Abstinence at 12-month Follow-up — 56; 54 Participants
Anemia · Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 1.26; 1.58 Grams per deciliter (g/dL)
ADHD · Substance Use Disorders
Primary: Change From Baseline in Symptoms: ADHD Symptoms (Inattention, Hyperactivity/Impulsivity) and Comorbid Problems (Conduct and Mood Problems, Substance Use). — 6.42; 6.90…